查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869724

癌症和腫瘤生物標記檢測市場規模、佔有率和趨勢分析報告：按癌症類型、生物標記類型、最終用途、地區和細分市場預測（2025-2033 年）

Cancer And Tumor Biomarker-based Assay Market Size, Share & Trends Analysis Report By Cancer Type, By Biomarker Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

癌症和腫瘤生物標記檢測市場摘要

2024年全球癌症和腫瘤生物標記檢測市場規模估計為109.7億美元，預計2033年將達到268.1億美元。

預計2025年至2033年間，該市場將以10.50%的複合年成長率成長，這主要得益於對早期診斷、個人化治療和精準腫瘤學日益成長的需求。生物標記檢測（包括基因組、蛋白質組和代謝組標記）使臨床醫生能夠更早發現癌症、預測疾病進展並更準確地指導治療方法方案的選擇。

次世代定序(NGS)、液態生物檢體和多重免疫檢測等技術進步提高了檢測的靈敏度和通量，同時縮短了周轉時間。製藥公司正擴大與診斷開發商合作，開發標靶治療的伴隨診斷，這進一步推動了市場成長。

分析平台的快速發展正在變革生物標記檢測。次世代定序(NGS) 平台具有速度更快、成本更低、靈活性更高的優勢，能夠進行廣泛的基因組檢測、腫瘤譜分析以及大規模發現罕見突變。這推動了對檢測方法開發和臨床應用的需求。同時，液態生物檢體（cfDNA、CTC、外泌體）能夠以微創的方式進行連續監測、早期檢測和追蹤治療抗藥性，其便捷性使得檢測範圍超越了僅依賴組織檢體的工作流程。多重 PCR/免疫檢測平台和數位病理/影像生物標記進一步實現了少量檢體中多種標記物的同步檢測，從而提高了診斷準確性並降低了每次有效檢測的成本。這些技術共同降低了每次檢測的成本，加快了某些工作流程的檢測速度，並開啟了新的臨床應用情境（篩檢、微量殘存疾病(MRD) 檢測和監測）。所有這些都擴大了潛在市場，並吸引了診斷公司和製藥合作方的投資。

標靶癌症治療的興起，使得藥物與生物標記檢測緊密結合，從而能夠識別合格的患者。隨著標靶治療和免疫療法核准，這些療法與特定的基因組、蛋白質組或免疫學特徵相關聯，製藥公司越來越需要檢驗的伴隨診斷試劑盒用於臨床試驗和監管核准。這推動了對各種適應症的臨床檢驗生物標記檢測的需求，也使得與昂貴治療方法直接相關的檢測具有較高的單次檢測成本。此外，全面基因組分析的廣泛應用以及腫瘤獨立性核准的擴展，也促進了多重檢測和組合檢測的使用，使得資金更多地投入到能夠指導多種治療決策的檢測上。這些趨勢正在推動診斷公司和藥物研發公司之間的併購與合作，加速生物標記檢測在全球的商業化應用。

用於治療選擇的生物標記檢測，尤其是伴隨診斷，面臨嚴格的監管流程，這會影響產品上市時間和商業化成本。監管機構要求進行嚴格的分析和檢驗檢驗，通常要求與治療藥物核准同時或配合提交。此外，新型生物標記和罕見突變也增加了檢驗研究的檢體採集難度。不同的區域法規結構（例如，FDA、EMA 以及不斷變化的體外診斷（IVD）法規）也增加了全球推廣的複雜性，並可能導致在不同地區重複進行研究和標籤差異。此外，監管機構越來越關注臨床效用和真實世界表現，迫使製造商提供上市後證據並實施品質系統（符合體外診斷醫療器材法規 (IVDR) 要求、產生臨床證據）。雖然這會增加研發時間和資本支出 (CAPEX)，但最終會提高臨床可靠性和支付方的接受度。

目錄

第1章 癌症和腫瘤生物標記檢測市場：調查方法和範圍

2. 癌症和腫瘤生物標記檢測市場：執行摘要

  • 市場概述
  • 癌症類型和生物標記類型概覽
  • 最終用途簡介
  • 競爭格局概覽

第3章 癌症和腫瘤生物標記檢測市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
    • 對癌症早期檢測的需求日益成長
    • 分子診斷和生物標記發現的進展
    • 癌症發生率上升和個人化醫療的引入
  • 市場限制因素分析
    • 生物標記檢測高成本
    • 監管和報銷方面的挑戰
  • 波特五力分析
  • PESTLE分析

第4章 癌症和腫瘤生物標記檢測市場：癌症類型評估和趨勢分析

  • 癌症和腫瘤生物標記檢測市場：癌症類型差異分析
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 卵巢癌
  • 其他

第5章 癌症和腫瘤生物標記檢測市場：生物標記類型估算和趨勢分析

  • 癌症和腫瘤生物標記檢測市場：生物標記類型差異分析
  • 遺傳/基因生物標記
  • 蛋白質生物標記
  • 表觀遺傳生物標記
  • 其他

6. 癌症和腫瘤生物標記檢測市場：終端用戶需求預測和趨勢分析

  • 癌症和腫瘤生物標記檢測市場：終端用途差異分析
  • 醫院和癌症中心
  • 診斷實驗室
  • 其他

7. 癌症和腫瘤生物標記檢測市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新產品上市
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市佔率分析，2024 年
  • 公司熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd,
    • Thermo Fisher Scientific, Inc.,
    • Illumina, Inc.
    • QIAGEN
    • Guardant Health
    • Exact Sciences Corporation
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Sysmex Corporation
    • Abbott
    • bioMerieux
    • Myriad Genetics, Inc.
    • Hologic, Inc.
    • Quest Diagnostics Incorporated
Product Code: GVR-4-68040-774-7

Cancer And Tumor Biomarker-based Assay Market Summary

The global cancer and tumor biomarker-based assay market size was estimated at USD 10.97 billion in 2024 and is projected to reach USD 26.81 billion by 2033, growing at a CAGR of 10.50% from 2025 to 2033, driven by the growing demand for early diagnosis, personalized treatment, and precision oncology. Biomarker assays-covering genomic, proteomic, and metabolomic markers-enable clinicians to detect cancers earlier, predict disease progression, and guide therapy selection with higher accuracy.

Advances in technologies such as next-generation sequencing (NGS), liquid biopsy, and multiplex immunoassays are enhancing assay sensitivity and throughput while reducing turnaround times. Pharmaceutical companies increasingly collaborate with diagnostic developers to create companion diagnostics for targeted therapies, further fueling market growth.

Rapid advances in analytic platforms are transforming biomarker testing. Next-generation sequencing (NGS) platforms have become faster, cheaper and more flexible, enabling broad genomic panels, tumor profiling and discovery of rare variants at scale - which drives demand for assay development and clinical adoption. Meanwhile, liquid biopsy (cfDNA, CTCs, exosomes) allows minimally invasive serial monitoring, early detection and therapy resistance tracking; its convenience expands testing volumes beyond tissue-only workflows. Multiplex PCR/immunoassay platforms and digital pathology/imaging biomarkers further enable simultaneous measurement of multiple markers from limited samples, improving diagnostic yield and cost per actionable result. Together these technologies lower per-test costs, shorten time-to-result for certain workflows, and unlock new clinical use cases (screening, MRD, monitoring), all of which expand total addressable market and invite investment from diagnostics firms and pharma co-development partners.

The shift to targeted oncology therapeutics has created a tight coupling between drugs and the biomarker tests that identify eligible patients. As more targeted therapies and immunotherapies receive approvals tied to specific genomic, proteomic or immunologic signatures, pharma companies increasingly require validated companion diagnostics for clinical trials and regulatory approval. This raises demand for clinically validated biomarker assays across indications and supports higher price-per-test economics when tests are linked directly to expensive therapies. Furthermore, broader adoption of comprehensive genomic profiling and tumor-agnostic approvals increases use of multiplex assays and panel testing, concentrating spend on assays that can guide multiple treatment decisions. These dynamics fuel M&A and partnerships between diagnostic companies and drug developers, accelerating commercial rollouts of biomarker assays globally.

Biomarker assays used for treatment selection-especially companion diagnostics-face stringent regulatory pathways that affect time-to-market and commercialization costs. Regulatory agencies require rigorous analytical validation, clinical validation, and often co-submission or alignment with therapeutic approvals; novel biomarkers or rare variants complicate sample accrual for validation studies. Varying regional frameworks (e.g., FDA, EMA, and evolving IVD rules) create complexity for global launches and can force iterative studies or label differences across geographies. Additionally, regulators increasingly scrutinize clinical utility and real-world performance, pushing manufacturers to generate post-market evidence and to adopt quality systems (IVDR compliance, clinical evidence generation), which raises development timelines and CAPEX but ultimately improves clinical confidence and payer acceptance.

Global Cancer And Tumor Biomarker-based Assay Market Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer and tumor biomarker-based assay market based on cancer type, biomarker type, end use, and region:

  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Others
  • Biomarker Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic / Genomic biomarkers
  • Protein biomarkers
  • Epigenetic biomarkers
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Cancer Centers
  • Diagnostic Laboratories
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Cancer and Tumor Biomarker-based Assay Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Cancer Type Segment
      • 1.1.1.2. Biomarker Type Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Cancer and Tumor Biomarker-based Assay Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Cancer Type and Biomarker Type Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Cancer and Tumor Biomarker-based Assay Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Growing demand for early cancer detection
    • 3.4.2. Advancements in molecular diagnostics and biomarker discovery
    • 3.4.3. Rising cancer prevalence and personalized medicine adoption
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of biomarker assays
    • 3.5.2. Regulatory and reimbursement challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Cancer and Tumor Biomarker-based Assay Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Cancer and Tumor Biomarker-based Assay Market: Cancer Type Movement Analysis
  • 4.2. Breast Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Lung Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Colorectal Cancer
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Prostate Cancer
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Ovarian Cancer
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cancer and Tumor Biomarker-based Assay Market: Biomarker Type Estimates & Trend Analysis

  • 5.1. Cancer and Tumor Biomarker-based Assay Market: Biomarker Type Movement Analysis
  • 5.2. Genetic / Genomic biomarkers
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Protein biomarkers
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Epigenetic biomarkers
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cancer and Tumor Biomarker-based Assay Market: End Use Estimates & Trend Analysis

  • 6.1. Cancer and Tumor Biomarker-based Assay Market: End Use Movement Analysis
  • 6.2. Hospitals and Cancer Centers
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Others
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cancer and Tumor Biomarker-based Assay Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Cancer and Tumor Biomarker-based Assay Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New product launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. F. Hoffmann-La Roche Ltd,
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Thermo Fisher Scientific, Inc.,
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Illumina, Inc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. QIAGEN
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Guardant Health
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Exact Sciences Corporation
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Bio-Rad Laboratories, Inc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Agilent Technologies, Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Sysmex Corporation
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Abbott
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. bioMerieux
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Myriad Genetics, Inc.
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Hologic, Inc.
      • 8.5.13.1. Company Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Quest Diagnostics Incorporated
      • 8.5.14.1. Company Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Cancer and Tumor Biomarker-based Assay Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 5 Global Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 6 Global Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 9 North America Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 10 North America Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 25 UK Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 26 UK Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 29 Germany Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 31 France Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 32 France Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 35 Italy Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 38 Spain Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 41 Sweden Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 44 Norway Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 , (USD Million)
  • Table 49 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 54 Japan Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 56 China Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 57 China Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 59 India Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 60 India Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 63 Australia Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 66 Thailand Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 69 South Korea Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 73 Latin America Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 76 Brazil Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 79 Argentina Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 83 MEA Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 86 South Africa Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 92 UAE Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global cancer and tumor biomarker-based assay market- Key market driver analysis
  • Fig. 7 Global cancer and tumor biomarker-based assay market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global cancer and tumor biomarker-based assay market - Porter's analysis
  • Fig. 10 Global cancer and tumor biomarker-based assay market - PESTEL analysis
  • Fig. 11 Global cancer and tumor biomarker-based assay market cancer Type outlook key takeaways
  • Fig. 12 Global cancer and tumor biomarker-based assay market: cancer Type movement analysis
  • Fig. 13 Breast cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Lung cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Prostate cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Ovarian cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Global cancer and tumor biomarker-based assay market biomarker type outlook key takeaways
  • Fig. 20 Global cancer and tumor biomarker-based assay market: biomarker type movement analysis
  • Fig. 21 Genetic / Genomic biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Protein biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Epigenetic biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Global cancer and tumor biomarker-based assay market end use outlook key takeaways
  • Fig. 26 Global cancer and tumor biomarker-based assay market: end use movement analysis
  • Fig. 27 Hospitals and cancer centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Global cancer and Tumor Biomarker-based Assay market: Regional movement analysis
  • Fig. 32 North America cancer and Tumor Biomarker-based Assay market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 37 UK cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 39 France cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 40 Spain cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 42 Denmark cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 45 Asia Pacific cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 46 Japan cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 47 China cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 48 India cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 49 South Korea cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 50 Australia cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 51 Thailand cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 52 Latin America cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 53 Brazil cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 54 Argentina cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 55 MEA cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 56 South Africa cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 57 Saudi Arabia cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 58 UAE cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 59 Kuwait cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 60 Strategy framework